Genomics

Dataset Information

0

Henderson omalizumab study


ABSTRACT: A considerable proportion of patients with H1-antihistamine-resistant chronic spontaneous urticaria (CSU) fails to respond to omalizumab. However, there is yet no available biomarker that accurately predicts such a response outcome. The utility of blood basophil and eosinophil levels and exosomal and basophil micro(mi)RNAs as biomarkers of response to omalizumab in CSU was explored. In this prospective cohort study of twenty patients with antihistamine-resistant CSU, subjects were treated with 3-monthly doses of omalizumab, and their response assessed using the weekly urticaria activity score (UAS7) for a period of 12-weeks. Basophil and eosinophil levels in the blood and differentially expressed exosomal and basophil miRNAs of complete responders compared to non-responders were identified at baseline. Canonical pathways, altered by differentially expressed miRNAs, were identified using Ingenuity Pathway Analysis (IPA). Complete responders had higher baseline basophil levels (≥21 cells/L) in the peripheral blood compared to non-responders (P = 0.005). Baseline levels of eosinophils did not differ between the study groups. Complete responders in comparison to non-responders had an expression profile characterized by a significantly higher expression of six exosomal miRNAs (miR-6499-5p, miR-7848, miR-4494-3p, miR-450a-2-3p, miR-6877-3p, and miR-3976) and lower expression of miR-141-3p. Complete responders also had higher expression of three basophil miRNAs (miR-1200, miR-1236-3p, and miR-4496). The exosomal miRNA expression profile was predicted by IPA to alter Tec Kinase Signaling pathway activity (P = 0.003).

ORGANISM(S): Homo sapiens

PROVIDER: GSE153579 | GEO | 2021/11/16

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2021-06-21 | GSE178500 | GEO
2021-08-04 | E-MTAB-10414 | biostudies-arrayexpress
2021-08-04 | E-MTAB-10421 | biostudies-arrayexpress
2015-11-10 | E-GEOD-74829 | biostudies-arrayexpress
2022-01-26 | GSE185516 | GEO
2022-09-15 | GSE176159 | GEO
| EGAD00001006842 | EGA
2020-02-21 | GSE130654 | GEO
| EGAS00001005296 | EGA
2022-08-31 | GSE202849 | GEO